Tamborero D, Gonzalez-Perez A, Perez-Llamas C, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3:2650. doi:10.1038/srep02650
Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113-20. doi:10.1038/ng.2764
Ellis MJ, Gillette M, Carr SA, et al. Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov. 2013;3(10):1108-12. doi:10.1158/2159-8290.CD-13-0219
Chmielecki J, Meyerson M. DNA sequencing of cancer: what have we learned? Annu Rev Med. 2014;65:63-79. doi:10.1146/annurev-med-060712-200152
Polak P, Lawrence MS, Haugen E, et al. Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair. Nat Biotechnol. 2014;32(1):71-5. doi:10.1038/nbt.2778
Shen RR, Zhou AY, Kim E, et al. TRAF2 is an NF-κB-activating oncogene in epithelial cancers. Oncogene. 2015;34(2):209-16. doi:10.1038/onc.2013.543
Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495-501. doi:10.1038/nature12912
Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1-2):317-31. doi:10.1016/j.cell.2013.12.010
Nilsson R, Jain M, Madhusudhan N, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014;5:3128. doi:10.1038/ncomms4128
Skates SJ, Gillette MA, LaBaer J, et al. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res. 2013;12(12):5383-94. doi:10.1021/pr400132j